SCHEDULE: Shareholder Group Opposes Sinovac Biotech Board Proposals Amidst Ongoing Litigation

1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited, led by Dr. Chiang Li, have voted their significant stake against proposals to remove and replace the current board of Sinovac Biotech Ltd., highlighting ongoing corporate governance disputes and litigation.

Summary

• 1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited (the 'reporting persons') filed Amendment No. 4 to their Schedule 13D regarding Sinovac Biotech Ltd.
• The reporting persons beneficially own an aggregate of 18,515,315 Common Shares, representing 32.3% of Sinovac's outstanding shares.
• Dr. Chiang Li, Chairman of both reporting persons and current Chairman of Sinovac's board, voted 6,812,855 Common Shares against two proposals at a Special Meeting scheduled for July 8, 2025.
• The first proposal seeks to remove current board members (excluding Dr. Li), and the second proposal seeks to replace them with a new slate of directors.
• 1Globe Biomedical (Hong Kong) Company Limited instructed CDH Utopia Limited to vote 4,200,000 Subject Shares against both proposals.
• Dr. Li also asked related parties holding 5,702,460 Common Shares to vote against both proposals.
• Dr. Li was nominated by SAIF for the alternative slate of directors but stated he would vote against both proposals in support of the current Board.
• The percentage of ownership is calculated based on 57,281,861 shares outstanding as of December 31, 2017, as reported in the 2018 20-F, excluding shares purportedly issued after May 2018 due to ongoing litigation.

Sentiment

Score: 4

Explanation: The document reveals significant internal corporate governance conflict and ongoing litigation, which typically creates uncertainty and can negatively impact a company's stability and investor perception. While the reporting persons are taking a clear stance, the underlying disputes are a concern.

Positives

• Dr. Chiang Li, a significant shareholder and current Chairman, is actively engaged in the company's corporate governance.
• The reporting persons are transparently disclosing their voting intentions and beneficial ownership.

Negatives

• Ongoing corporate governance disputes and litigation create uncertainty and potential instability for the company.
• A Special Meeting has been called by another shareholder (SAIF) to remove and replace most of the current board, indicating significant internal conflict.
• The dispute over 'Exchange Shares' and 'Disputed PIPE' issuances suggests potential issues with past share issuances and capital structure.

Risks

• Ongoing litigation related to the issuance of 'Exchange Shares' and 'Disputed PIPE' shares.
• Risk of significant changes to the Board of Directors if the proposals at the Special Meeting pass, potentially leading to leadership instability.
• Uncertainty regarding the total shares outstanding due to disputed share issuances.

Future Outlook

Dr. Chiang Li stated his intention to continue serving on the Board if shareholders vote for both proposals at the Special Meeting, despite his vote against them. The outcome of the Special Meeting on July 8, 2025, will determine the future composition of the Board.

Management Comments

• Dr. Li stated that he would continue to serve on the Board in the event the shareholders voted for both proposals at the Special Meeting.
• Dr. Li also made it clear that he would vote against both proposals at the Special Meeting in support of the current Board.

Industry Context

This filing highlights a significant corporate governance dispute within a biotechnology company, a common occurrence in industries with high growth potential and complex ownership structures, particularly in cross-border investments involving Chinese companies. Such disputes can impact investor confidence and operational stability.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing litigation concerning the issuance of 'Exchange Shares' and the 'Disputed PIPE' (Private Investment in Public Equity).
• 1Globe Capital and OrbiMed Advisors LLC are co-defendants in multiple lawsuits filed by affiliates of Vivo Capital LLC and Advantech Capital Partners Ltd.'s affiliate Prime Success, L.P.
• 1Globe Capital and OrbiMed are co-plaintiffs in one action related to the Disputed PIPE.
• The Board is seeking to fulfill its fiduciary duty to implement the Judgment issued by the Privy Council on January 16, 2025, and the Privy Council's Order dated February 5, 2025.

Related Party Transactions

• 5,702,460 Common Shares are held by 'related parties of the reporting persons,' included in the beneficial ownership pursuant to an SEC order, though the reporting persons do not admit beneficial ownership.
• CDH Utopia Limited holds 'Subject Shares' for which 1Globe Biomedical (Hong Kong) Company Limited possesses voting rights (70% of Subject Shares) and certain financial upside for 6,000,000 Common Shares.

Stakeholder Impact

• Shareholders: Significant impact due to potential changes in board composition, ongoing litigation, and uncertainty regarding the company's future strategic direction and stability. The dispute over share issuances could affect share value and voting power.
• Management/Employees: Potential for leadership changes and instability, which could affect morale and operational continuity.
• Creditors: Potential impact on financial stability and risk profile due to ongoing litigation and governance disputes.

Next Steps

• The Special Meeting of Sinovac Biotech Ltd. shareholders is scheduled for July 8, 2025, where proposals to remove and replace board members will be voted upon.

Key Dates

Recommendation

Keywords

Sinovac Biotech, Schedule 13D, 1Globe Capital, 1Globe Biomedical, Chiang Li, corporate governance, shareholder activism, proxy vote, board of directors, litigation, common shares, beneficial ownership, SEC filing